<DOC>
	<DOCNO>NCT02509234</DOCNO>
	<brief_summary>The purpose study evaluate patient refractory childhood sarcoma , treat combination therapy trabectedin irinotecan ( within compassionate use ) , determine , promise treatment option acceptable toxicity result warrant prospective study .</brief_summary>
	<brief_title>Trabectedin Irinotecan Refractory Pediatric Sarcomas</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>Adolescents young adult ( age10 40 yoa ) refractory sarcoma , presently treatment option EUROEwing/ EURAMOS/CWS ( i.e . â‰¥ second relapse ES , resistance surgery osteosarcoma , relapse rhabdomyosarcoma ) treat combined chemotherapy trabectedin irinotecan ( describe intervention ) exist match control exist study database start treatment within three month last progress Key Patients newly diagnose first relapse .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>pediatric sarcoma</keyword>
	<keyword>Ewing sarcoma</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>soft tissue sarcoma</keyword>
</DOC>